Precision Diagnosis, Intelligent Navigation: The Technological Leap Of Breast Biopsy Needles From Minimally Invasive Sampling To Therapeutic Decision-Making

Precision Diagnosis, Intelligent Navigation: The Technological Leap of Breast Biopsy Needles from Minimally Invasive Sampling to Therapeutic Decision-Making

Breast biopsy needle technology is undergoing a profound transformation, evolving from traditional puncture procedures towards intelligent and precise methodologies. The widespread adoption of Vacuum-Assisted Biopsy (VAB) technology and the innovative introduction of Artificial Intelligence (AI) navigation systems are reshaping the clinical standards and operational paradigms for minimally invasive breast diagnosis.

Efficacy Breakthrough in Vacuum-Assisted Biopsy (VAB) Technology

Vacuum-assisted biopsy devices utilize negative pressure adsorption to acquire tissue, effectively minimizing cellular structural damage caused by mechanical cutting. Compared to traditional core needle biopsy, VAB systems can obtain more complete and sufficient samples, with a single sampling volume potentially exceeding 20mg while keeping the cell degeneration rate below 5%. Research data from 2025 indicates that VAB demonstrates excellent diagnostic performance in the active surveillance of low-risk ductal carcinoma in situ (LR-DCIS), achieving sensitivity and specificity rates as high as 95.28% and 100%, respectively. Notably, for suspicious microcalcifications in women under 40, the malignant detection rate via VAB (16.1%) is significantly lower than that in women over 50 (20.8%), with B3 atypical lesions being rare in the younger group. This highlights its unique value in the differential diagnosis for younger populations.

AI Navigation Systems: The Key Technology Enabling Surgical Precision

The successful application of a real-time AI navigation system, developed based on the YOLOv11 architecture, in vacuum-assisted breast biopsy marks the formal entry of this field into the intelligent era. Trained and validated on 22,278 ultrasound images, the system significantly outperforms junior physicians in tumor detection (mAP50=0.907) and biopsy channel positioning (mAP50=0.671), achieving real-time processing capability of 1.2 ms per frame on a GPU platform. This technological breakthrough fundamentally addresses critical clinical pain points such as the high dependence on ultrasound guidance and the difficulty beginners face with needle positioning during VABB procedures. As the first dedicated intelligent navigation tool for VABB surgery, it holds milestone clinical significance for shortening the learning curve for physicians and comprehensively enhancing surgical precision.

Multimodal Image Fusion: Constructing 3D Visualized Puncture Pathways

The deep integration of multimodal imaging technologies-ultrasound, CT, MRI-enables "three-dimensional visualized precision puncture." For instance, a domestic biopsy needle system uses AI algorithms to intelligently superimpose pre-operative CT images with intraoperative real-time ultrasound, automatically and accurately marking lesion locations, controlling puncture errors within 0.5 mm. In lung biopsy for peripheral nodules, this technology has increased the sampling success rate to over 95%. Furthermore, the combination of electromagnetic navigation and robotic assistance allows robotic bronchoscopy platforms (e.g., the ION system) equipped with flexible biopsy needles to accurately reach peripheral lung lesions, expanding the application boundaries of minimally invasive biopsy.

Structural Optimization and Intelligent Sensory Design

The new generation of biopsy needles has achieved multiple innovations in the instrument's structure and functional design:

1. Vacuum Coaxial Technology: Enables multiple samplings through a single puncture, avoiding additional damage to surrounding tissues from repeated insertions.

2. Intelligent Pressure Feedback System: Integrates micro pressure sensors to monitor resistance changes in real-time during the puncture. When the needle tip approaches critical blood vessels or nerves, the system can automatically adjust the insertion speed or issue warnings. In animal experiments, this has reduced the probability of accidental injury to vital structures to below 2%, significantly improving procedural safety.

Pioneering a Fundamental Shift in Treatment Paradigms

Research published in JAMA Oncology in March 2025 reveals an even more profound impact: For HER2-positive or triple-negative breast cancer patients who achieved pathological complete response (pCR) confirmed by image-guided VAB after neoadjuvant systemic therapy, those who received radiotherapy alone (omitting surgery) showed a 0% 5-year rate of ipsilateral breast tumor recurrence, with both 5-year disease-free survival and overall survival rates reaching 100%. This study is the first to confirm that, by precisely identifying pCR patients through biopsy technology, radiotherapy can sufficiently replace traditional surgery, with reliable long-term efficacy. This suggests that breast biopsy technology is transcending its role as a mere diagnostic tool and is beginning to directly participate in and influence major treatment decisions, potentially guiding a profound transformation in the future treatment model for breast cancer.